Scientists Block Brain Protein That Drives Parkinson's Disease Spread

Parkinson's disease affects over one million Americans, and while current treatments manage symptoms like tremors and balance problems, none have been shown to slow the disease itself. A new study from the University of Pennsylvania's Perelman School of Medicine, published in the journal Neuron, identifies a promising molecular target that could change this reality.

The key player is a protein called GPNMB — glycoprotein nonmetastatic melanoma B. Researchers found that when neurons in the brain become damaged by Parkinson's-related processes, nearby immune cells called microglia ramp up production of GPNMB. Enzymes then cleave part of the protein free, allowing it to travel between cells and accelerate the spread of toxic alpha-synuclein clumps — the hallmark of Parkinson's disease pathology.

This creates a self-reinforcing cycle: alpha-synuclein damages neurons, which triggers microglia to release GPNMB, which in turn helps alpha-synuclein spread to healthy neurons, causing further damage. The team developed monoclonal antibodies targeting GPNMB and tested them in cultured neuron experiments. The antibodies successfully interrupted this cycle, preventing the toxic protein from moving between cells.

The practical implications are significant. Because many Parkinson's patients are diagnosed in early stages when symptoms are still mild, a therapy that slows progression from the outset could dramatically preserve quality of life and cognitive function over time. This approach targets the disease mechanism itself — not just downstream symptoms.

However, important caveats apply. These results come from preclinical laboratory experiments using cultured neurons, not animal models or human trials. The jump from cell culture to clinical treatment is substantial and often lengthy. Researchers will need to demonstrate safety and efficacy across multiple stages of development before GPNMB-blocking antibodies could reach patients. Still, this represents a scientifically grounded and novel direction in neurodegeneration research.